Technical Data
Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Mouse (GM-CSF, Burst Promoting Activity, CMCSF, Colony Stimulating Factor 2, CSF Alpha, Eosinophil Colony Stimulating Factor, Granulocyte Macrophage Colony Stimulating Factor, Molgramostin, Pl
Molecular Biology Storage: -20CShipping: Blue Ice
M-GM-CSF is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. GM-CSF receptors shows significant homologies with other receptors for hematopoietic growth factors, including IL2-beta, IL-3, IL-6, IL-7, EPO and the Prolactin receptors.

Biological Activity:
Murine GM-CSF is fully biologically active when compared to standard. The ED50 as determined by the dose-dependent proliferation of murine FDC-P1 cell line is 3-5pg/ml..

Amino Acid Sequence:

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, 0.1% BSA or HSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: E. coli
Purity: ~ 95% as determined by HPLC; Reducing and non-reducing SDS-PAGE (UV 280NM) spectroscopy at 280nm.
Form: Supplied as a lyophilized powder from 10mM acetic acid. Reconstitute with sterile ddH2O, and a carrier protein (0.1% HSA or BSA) to a concentration of 0.1mg/ml, which can be further diluted into other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Circadian changes in granulocyte-macrophage colony-stimulating factor message in circulating eosinophils. Ann Allergy Asthma Immunol 2007 Jan;98(1):75-82 2. Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK. Invest Ophthalmol Vis Sci 2007 Jan;48(1):277-84 3. Long term administration of granulocyte-macrophage colony stimulating factor decreases development of 1-2 dimethylhydrazine-induced colon cancer in rats. J Surg Oncol 2007 Jan 1;95(1):12-21 4. Papillary thyroid carcinoma producing granulocyte-macrophage colony-stimulating factor is associated with neutrophilia and eosinophilia. Hormones (Athens) 2006 Oct-Dec;5(4):303-9 5. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006 Nov 15;12(22):6737-47 6. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006 Nov 20;24(33):5207-15

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.